Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19
Background: Emerging studies have described and analyzed epidemiological, clinical, laboratory, and radiological features of COVID-19 patients. Yet, scarce information is available regarding the association of lipid profile features and disease severity and mortality.Methods: We conducted a prospect...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-12-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2020.584987/full |
id |
doaj-82636c55a49b4fba9626adea2dd50a9c |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jia Teng Sun Jia Teng Sun Zhongli Chen Peng Nie Peng Nie Heng Ge Heng Ge Long Shen Long Shen Fan Yang Fan Yang Xiao Long Qu Xiao Long Qu Xiao Ying Ying Xiao Ying Ying Yong Zhou Yong Zhou Wei Wang Wei Wang Min Zhang Min Zhang Jun Pu |
spellingShingle |
Jia Teng Sun Jia Teng Sun Zhongli Chen Peng Nie Peng Nie Heng Ge Heng Ge Long Shen Long Shen Fan Yang Fan Yang Xiao Long Qu Xiao Long Qu Xiao Ying Ying Xiao Ying Ying Yong Zhou Yong Zhou Wei Wang Wei Wang Min Zhang Min Zhang Jun Pu Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19 Frontiers in Cardiovascular Medicine HDL-C apoA-1 inflammation lipid COVID-19 |
author_facet |
Jia Teng Sun Jia Teng Sun Zhongli Chen Peng Nie Peng Nie Heng Ge Heng Ge Long Shen Long Shen Fan Yang Fan Yang Xiao Long Qu Xiao Long Qu Xiao Ying Ying Xiao Ying Ying Yong Zhou Yong Zhou Wei Wang Wei Wang Min Zhang Min Zhang Jun Pu |
author_sort |
Jia Teng Sun |
title |
Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19 |
title_short |
Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19 |
title_full |
Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19 |
title_fullStr |
Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19 |
title_full_unstemmed |
Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19 |
title_sort |
lipid profile features and their associations with disease severity and mortality in patients with covid-19 |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Cardiovascular Medicine |
issn |
2297-055X |
publishDate |
2020-12-01 |
description |
Background: Emerging studies have described and analyzed epidemiological, clinical, laboratory, and radiological features of COVID-19 patients. Yet, scarce information is available regarding the association of lipid profile features and disease severity and mortality.Methods: We conducted a prospective observational cohort study to investigate lipid profile features in patients with COVID-19. From 9 February to 4 April 2020, a total of 99 patients (31 critically ill and 20 severely ill) with confirmed COVID-19 were included in the study. Dynamic alterations in lipid profiles were recorded and tracked. Outcomes were followed up until 4 April 2020.Results: We found that high-density lipoprotein-cholesterol (HDL-C) and apolipoprotein A-1 (apoA-1) levels were significantly lower in the severe disease group, with mortality cases showing the lowest levels (p < 0.0001). Furthermore, HDL-C and apoA-1 levels were independently associated with disease severity (apoA-1: odds ratio (OR): 0.651, 95% confidence interval (CI): 0.456–0.929, p = 0.018; HDL-C: OR: 0.643, 95% CI: 0.456–0.906, p = 0.012). For predicting disease severity, the areas under the receiver operating characteristic curves (AUCs) of HDL-C and apoA-1 levels at admission were 0.78 (95% CI, 0.70–0.85) and 0.85 (95% CI, 0.76–0.91), respectively. For in-hospital deaths, HDL-C and apoA-1 levels demonstrated similar discrimination ability, with AUCs of 0.75 (95% CI, 0.61–0.88) and 0.74 (95% CI, 0.61–0.88), respectively. Moreover, patients with lower serum concentrations of apoA-1 (<0.95 g/L) or HDL-C (<0.84 mmol/l) had higher mortality rates during hospitalization (log-rank p < 0.001). Notably, levels of apoA-1 and HDL-C were inversely proportional to disease severity. The survivors of severe cases showed significant recovery of apoA-1 levels at the end of hospitalization (vs. midterm apoA-1 levels, p = 0.02), whereas the mortality cases demonstrated continuously lower apoA-1 levels throughout hospitalization. Correlation analysis revealed that apoA-1 and HDL-C levels were negatively correlated with both admission levels and highest concentrations of C-reactive protein and interleukin-6.Conclusions: Severely ill COVID-19 patients featured low HDL-C and apoA-1 levels, which were strongly correlated with inflammatory states. Thus, low apoA-1 and HDL-C levels may be promising predictors for severe disease and in-hospital mortality in patients suffering from COVID-19. |
topic |
HDL-C apoA-1 inflammation lipid COVID-19 |
url |
https://www.frontiersin.org/articles/10.3389/fcvm.2020.584987/full |
work_keys_str_mv |
AT jiatengsun lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT jiatengsun lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT zhonglichen lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT pengnie lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT pengnie lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT hengge lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT hengge lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT longshen lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT longshen lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT fanyang lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT fanyang lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT xiaolongqu lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT xiaolongqu lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT xiaoyingying lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT xiaoyingying lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT yongzhou lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT yongzhou lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT weiwang lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT weiwang lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT minzhang lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT minzhang lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 AT junpu lipidprofilefeaturesandtheirassociationswithdiseaseseverityandmortalityinpatientswithcovid19 |
_version_ |
1724390861286932480 |
spelling |
doaj-82636c55a49b4fba9626adea2dd50a9c2020-12-08T08:34:56ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2020-12-01710.3389/fcvm.2020.584987584987Lipid Profile Features and Their Associations With Disease Severity and Mortality in Patients With COVID-19Jia Teng Sun0Jia Teng Sun1Zhongli Chen2Peng Nie3Peng Nie4Heng Ge5Heng Ge6Long Shen7Long Shen8Fan Yang9Fan Yang10Xiao Long Qu11Xiao Long Qu12Xiao Ying Ying13Xiao Ying Ying14Yong Zhou15Yong Zhou16Wei Wang17Wei Wang18Min Zhang19Min Zhang20Jun Pu21Division of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaInstitute of Cardiovascular Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDivision of Pulmonary and Critical Care Medicine, Leishenshan Hospital, Wuhan, ChinaDivision of Cardiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaBackground: Emerging studies have described and analyzed epidemiological, clinical, laboratory, and radiological features of COVID-19 patients. Yet, scarce information is available regarding the association of lipid profile features and disease severity and mortality.Methods: We conducted a prospective observational cohort study to investigate lipid profile features in patients with COVID-19. From 9 February to 4 April 2020, a total of 99 patients (31 critically ill and 20 severely ill) with confirmed COVID-19 were included in the study. Dynamic alterations in lipid profiles were recorded and tracked. Outcomes were followed up until 4 April 2020.Results: We found that high-density lipoprotein-cholesterol (HDL-C) and apolipoprotein A-1 (apoA-1) levels were significantly lower in the severe disease group, with mortality cases showing the lowest levels (p < 0.0001). Furthermore, HDL-C and apoA-1 levels were independently associated with disease severity (apoA-1: odds ratio (OR): 0.651, 95% confidence interval (CI): 0.456–0.929, p = 0.018; HDL-C: OR: 0.643, 95% CI: 0.456–0.906, p = 0.012). For predicting disease severity, the areas under the receiver operating characteristic curves (AUCs) of HDL-C and apoA-1 levels at admission were 0.78 (95% CI, 0.70–0.85) and 0.85 (95% CI, 0.76–0.91), respectively. For in-hospital deaths, HDL-C and apoA-1 levels demonstrated similar discrimination ability, with AUCs of 0.75 (95% CI, 0.61–0.88) and 0.74 (95% CI, 0.61–0.88), respectively. Moreover, patients with lower serum concentrations of apoA-1 (<0.95 g/L) or HDL-C (<0.84 mmol/l) had higher mortality rates during hospitalization (log-rank p < 0.001). Notably, levels of apoA-1 and HDL-C were inversely proportional to disease severity. The survivors of severe cases showed significant recovery of apoA-1 levels at the end of hospitalization (vs. midterm apoA-1 levels, p = 0.02), whereas the mortality cases demonstrated continuously lower apoA-1 levels throughout hospitalization. Correlation analysis revealed that apoA-1 and HDL-C levels were negatively correlated with both admission levels and highest concentrations of C-reactive protein and interleukin-6.Conclusions: Severely ill COVID-19 patients featured low HDL-C and apoA-1 levels, which were strongly correlated with inflammatory states. Thus, low apoA-1 and HDL-C levels may be promising predictors for severe disease and in-hospital mortality in patients suffering from COVID-19.https://www.frontiersin.org/articles/10.3389/fcvm.2020.584987/fullHDL-CapoA-1inflammationlipidCOVID-19 |